The final analysis of the PEONY study is out in Nature Communications The addition of pertuzumab to (neo)adjuvant trastuzumab and CT for Asian patients with HER2+ BC ⬆️ not only pCR but also survival ➡️5-Year EFS 84.8% vs. 73.7% (HR 0.53; 0.32–0.89) OncoAlert nature.com/articles/s4146…

MLX is in AI conferences now Riccardo Musmeci Awni Hannun Also MLX-Image is on Hugging Face Hub 🤗 It's very similar to PyTorch if you want to get started: huggingface.co/docs/hub/main/…

Now out in #ClinicalBreastCancer our subanalysis of the #CLEOPATRA study led by Véronique Debien showing that patients with radiological complete response at 1️⃣st disease re-evaluation have significantly ⬆️ survival OncoAlert authors.elsevier.com/c/1inrj5RAAopu…

Ribociclib plus Endocrine Therapy in Early Breast Cancer : NATALEE 3y-iDFS: 90.4% vs 87.1% (HR:0.75) nejm.org/doi/full/10.10…

In this analysis led by Véronique Debien, MD, MSc, findings from the CLEOPATRA trial suggest that radiological complete response at first imaging re-evaluation in HER2-positive metastatic breast cancer patients predicts longer PFS and OS.

Does HER2-low expression impact the incidence of CNS disease from breast cancer? Large analysis (n≃20.000) from the ESME database shows similar incidence and outcomes for brain mets & LMD between HER2-low vs HER2-0 MBC, but higher incidence in HER2+. Published in ESMO Open 🔥

Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival or quality of life within 5 years of accelerated approval. ja.ma/3yahWBT

At the #AI for #Oncology congress, we presented our research on #SD generated through #GANs to augment a dataset of HR+/HER2- eBC. SD mirrored the characteristics of the real cohort while ensuring privacy protection. This support multimodal data integration with AI in oncology

Less than 48h to #ESMOBreast24: time for the #top10 abstracts. Highly awaited readout from IMp132, safety update of important ph 3 trials (TB01, NATALEE), intriguing biomarker analyses from large datasets (HER2DX, monarchE) and much more. Promises to be a terrific congress! #bcsm

Determining when to escalate or descalate treatment in HER2+ breast cancer requires additional clinical trials. Evandro de Azambuja, MD, PhD ESMO - Eur. Oncology #ESMOBreast24

✔️we develop a #ML tool to predict #RSClin to refine DR risk and CT benefit for HR+HER2- #earlyBC ✔️our tool can accurately reproduce RSClin ✔️free web based link to access the tool ➡️ lnkd.in/dUk-EUrP ✔️this tool may support treatment decision for HR+ eBC #ESMOBreast24

🗞 hot off the press ESMO - Eur. Oncology #RealWorldData & #DigitalOncology 📢 #RWE use for pre-authorisation efficacy evaluation reported in 21% of targeted therapy approvals for solid malignancies 📈 from 2018 to 2022 ✅️ 75% supportive 📍Data revisited focusing on #bcsm #ESMOBreast24

#ESMOBreast24 is getting to the end. Another fulfilling experience - very proud to have been awarded with a ESMO - Eur. Oncology Merit travel grant for our work🙏🏻 A big❤️to all colleagues and friends that made it possible and help improve #breastcancer care everyday OncoAlert Institut Jules Bordet Instituut

Most awaited results @ #ASCO24 on the topic of breast cancer ⏯️ stay tuned for OncoAlert selection on other topics 🛫🛫

Check out our last review on activity biomarker and toxicity of PI3K/Akt targeted agents led by Marianna Sirico published in Critical Reviews in Oncology Hematology (CROH) ⬇️⬇️

At #ESMO24 Nancy Lin, MD presents data on T-DXd in Destiny-Breast12 T-DXd showed substantial overall and intracranial clinical activity in pts with HER2+ mBC 🧠 Median PFS 17.3 mos and CNS ORR 72% in pts with baseline brain mets OncoAlert

Neo-CheckRay presented by Alex De Caluwe Ph2 II trial in early LumB BC, exploring NACT + SBRT + IO (anti-PD-L1, anti-CD73) The addition of IO to NACT+SBRT numerically improved RCB0/1 rates (38% vs 51%, P = 0.2) Incredibly proud to be part of this effort! OncoAlert

The mentorship is a KEY 🔑🚀 Evandro de Azambuja, MD, PhD

At #ESMO24 Evandro de Azambuja, MD, PhD talks about cardiac immune-related adverse events❤️‍🩹 Myocarditis has low incidence but high mortality risk⚠️ Up to 30% of myocarditis can be associated with other irAEs (myositis, myasthenia)‼️ Remind to rule out the “overlap syndrome” OncoAlert

Just attended the #ESMO advanced course on Antibody-Drug Conjugates #ADC in Zurich!🇨🇭 Excellent discussion on development, therapeutic application, future trials and management of toxicities of this innovative class of drugs 💊 Thank you ESMO - Eur. Oncology for this enriching experience!